期刊
CURRENT PHARMACEUTICAL DESIGN
卷 27, 期 21, 页码 2468-2481出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612826666201021130146
关键词
Rheumatoid arthritis; autoimmune disease; conventional drugs; novel drug delivery systems; lipogelosomes; nanosponges; lipo-somes; herbal drugs
资金
- Amity University Uttar Pradesh, Noida campus, India
Rheumatoid arthritis is an autoimmune disease with specific clinical manifestations, influenced by genetic, environmental, and immune factors. While current therapy has limitations, novel drug delivery systems offer potential breakthroughs to enhance the treatment efficacy in the future.
Rheumatoid arthritis (RA) is the most commonly occurring, progressive, autoimmune disease, affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery systems. The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional treatment with special reference to the role of novel drug delivery systems encapsulating anti-rheumatic drugs and herbal drugs in passive and receptor-mediated active targeting against RA. On reviewing the conventional and current therapeutics against RA, we conclude that although the current therapy for the treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective and appropriate treatment of this autoimmune disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据